Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-14 4:00 pm Sale | 2023-12-31 | 13G | InflaRx N.V. IFRX | TANG CAPITAL PARTNERS LP | 1,873,753 3.200% | -1,126,247 (-37.54%) | Filing History |
| 2024-02-14 4:00 pm Sale | 2023-12-31 | 13G | Kinnate Biopharma Inc. KNTE | TANG CAPITAL PARTNERS LP | 2,601,647 5.500% | -364,068 (-12.28%) | Filing History |
| 2024-02-14 4:00 pm Sale | 2023-12-31 | 13G | TCR2 Therapeutics Inc. TCRR | TANG CAPITAL PARTNERS LP | 0 0.000% | -4,215,864 (Position Closed) | Filing History |
| 2024-02-14 4:00 pm Unchanged | 2023-12-31 | 13G | Tonix Pharmaceuticals Holding Corp. TNXP | TANG CAPITAL PARTNERS LP | 0 0.000% | 0 (Unchanged) | Filing History |
| 2024-02-14 4:00 pm Sale | 2023-12-31 | 13G | Bellerophon Therapeutics, Inc. BLPH | TANG CAPITAL PARTNERS LP | 0 0.000% | -1,062,619 (Position Closed) | Filing History |
| 2024-02-14 4:00 pm Sale | 2023-12-31 | 13G | BioAtla, Inc. BCAB | TANG CAPITAL PARTNERS LP | 2,524,076 5.300% | -600,000 (-19.21%) | Filing History |
| 2024-02-14 4:00 pm Sale | 2023-12-31 | 13G | Bionomics Limited BNOX | TANG CAPITAL PARTNERS LP | 0 0.000% | -10,500,000 (Position Closed) | Filing History |
| 2024-02-14 4:00 pm Purchase | 2023-12-31 | 13G | Bolt Biotherapeutics, Inc. BOLT | TANG CAPITAL PARTNERS LP | 3,652,244 9.600% | 919,994 (+33.67%) | Filing History |
| 2024-02-14 4:00 pm Purchase | 2023-12-31 | 13G | CytomX Therapeutics, Inc. CTMX | TANG CAPITAL PARTNERS LP | 6,550,000 9.800% | 3,039,555 (+86.59%) | Filing History |
| 2024-02-14 4:00 pm Purchase | 2023-12-31 | 13G | Elevation Oncology, Inc. ELEV | TANG CAPITAL PARTNERS LP | 4,300,454 9.990% | 2,944,628 (+217.18%) | Filing History |
| 2024-02-14 4:00 pm Sale | 2023-12-31 | 13G | Genfit S.A. GNFT | TANG CAPITAL PARTNERS LP | 479,441 1.000% | -2,163,706 (-81.86%) | Filing History |
| 2024-02-14 4:00 pm Purchase | 2023-12-31 | 13G | KalVista Pharmaceuticals, Inc. KALV | TANG CAPITAL PARTNERS LP | 3,440,345 9.960% | 243,899 (+7.63%) | Filing History |
| 2024-02-14 4:00 pm Sale | 2023-12-31 | 13G | MEI Pharma, Inc. MEIP | TANG CAPITAL PARTNERS LP | 326,084 4.900% | -35,000 (-9.69%) | Filing History |
| 2024-02-14 4:00 pm Sale | 2023-12-31 | 13G | Pyxis Oncology, Inc. PYXS | TANG CAPITAL PARTNERS LP | 0 0.000% | -3,470,700 (Position Closed) | Filing History |
| 2024-02-14 4:00 pm Purchase | 2023-12-31 | 13G | Reviva Pharmaceuticals Holdings, Inc. RVPH | TANG CAPITAL PARTNERS LP | 3,098,615 9.990% | 832,386 (+36.73%) | Filing History |
| 2024-02-14 4:00 pm Purchase | 2023-12-31 | 13G | Tarsus Pharmaceuticals, Inc. TARS | TANG CAPITAL PARTNERS LP | 2,204,797 6.700% | 203,212 (+10.15%) | Filing History |
| 2024-02-14 4:00 pm Sale | 2023-12-31 | 13G | Tharimmune, Inc. THAR | TANG CAPITAL PARTNERS LP | 0 0.000% | -16,837 (Position Closed) | Filing History |
| 2024-02-05 4:49 pm Purchase | 2024-01-24 | 13G | Precision BioSciences, Inc. DTIL | TANG CAPITAL PARTNERS LP | 213,333 5.200% | 213,333 (New Position) | Filing History |
| 2024-02-05 4:48 pm Purchase | 2024-01-24 | 13G | Graphite Bio, Inc. GRPH | TANG CAPITAL PARTNERS LP | 445,406 5.400% | 445,406 (New Position) | Filing History |
| 2024-02-02 4:00 pm Sale | 2024-01-26 | 13D | Rain Enhancement Technologies Holdco Inc RAIN | TANG CAPITAL PARTNERS LP | 0 0.000% | -4,024,486 (Position Closed) | Filing History |